logo
  

Genentech : Ocrevus Data Show Benefit In Disability Progression & Cognitive Decline In SPMS & PPMS

Genentech, a member of the Roche Group (RHHBY), announced new Ocrevus (ocrelizumab) data that show its benefit on disease progression and cognitive outcomes in primary progressive multiple sclerosis or PPMS and secondary progressive MS or SPMS.

The company noted that 75% of patients with secondary progressive multiple sclerosis (SPMS) and primary progressive MS (PPMS) achieved no evidence of progression (NEP) in a one-year interim analysis of CONSONANCE study . The study is a first-of-its-kind open-label Phase IIIb trial to evaluate the effect of Ocrevus in SPMS and PPMS patients.

The company stated that 70% of patients with SPMS and PPMS demonstrated stable or improved cognition after one year of Ocrevus treatment in the study.

According to the company, separate analysis on treatment disparities showed fewer Black and Hispanic patients with MS initiate high-efficacy treatments within two years of diagnosis.

Ocrevus is approved in 100 countries across North America, South America, the Middle East, Eastern Europe, as well as in Australia, Switzerland, the United Kingdom and the EU.

Multiple sclerosis occurs when the immune system abnormally attacks the insulation and support around nerve cells (myelin sheath) in the central nervous system (brain, spinal cord and optic nerves), causing inflammation and consequent damage. This damage can cause a wide range of symptoms, including muscle weakness, fatigue and difficulty seeing, and may eventually lead to disability.

Ocrevus is the first and only therapy approved for both RMS (including RRMS and active, or relapsing, secondary progressive MS [SPMS], in addition to clinically isolated syndrome in the United States) and PPMS. Ocrevus is a humanized monoclonal antibody designed to target CD20-positive B cells, a specific type of immune cell thought to be a key contributor to myelin (nerve cell insulation and support) and axonal (nerve cell) damage.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Primal Pet Foods is recalling a single lot of Raw Frozen Primal Patties for Dogs Beef Formula due to potential contamination with Listeria monocytogenes, the U.S. Food and Drug Administration said. The recall involves lot #W10068709 of 6-pound Raw Frozen Primal Patties with best by date of 05/22/23. The Raw Frozen Primal Patties are sold in flexible packaging in the freezer at select pet stores. The U.S. Food and Drug Administration has authorized state-licensed pharmacists to prescribe COVID-19 pill Paxlovid (nirmatrelvir and ritonavir) by drug major Pfizer Inc. to eligible patients, with certain limitations. The agency has revised the Emergency Use Authorization or EUA for Paxlovid for the authorization, which could improve access for some patients at high risk for severe covid-19. Retail major Walmart's popular InHome direct-to-fridge delivery service is now available as an optional add-on within its membership plan Walmart+. Walmart also launched InHome service, which delivers groceries straight to one's fridge, in several new markets including Miami, Tampa, Orlando, Dallas, Austin, San Jose and San Francisco.
Follow RTT